Fulcrum Therapeutics, Inc. SEC filings FULC
Fulcrum Therapeutics, Inc. has 520 filings in SEC EDGAR's recent list, going back to Jul 25, 2016. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 17, 2026 (material agreement, unregistered share sale, change in control, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 4, 2026 | — |
| 425 | Filing | Aug 17, 2026 | — |
| 425 | Filing | Aug 17, 2026 | — |
| 425 | Filing | Aug 17, 2026 | — |
| DEFR14A | Filing | May 7, 2025 | — |
| EFFECT | Filing | Apr 25, 2024 | — |
| CORRESP | Letter to the SEC | Apr 24, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2024 | — |
| POS EX | Filing | May 9, 2022 | — |
| EFFECT | Filing | Apr 28, 2022 | — |
| POSASR | Filing | Mar 3, 2022 | — |
| SEC STAFF LETTER | Filing | Mar 22, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 22, 2021 | — |
| EFFECT | Filing | Aug 17, 2020 | — |
| CORRESP | Letter to the SEC | Aug 13, 2020 | — |
| EFFECT | Filing | Aug 12, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2020 | — |
| EFFECT | Filing | Jun 26, 2020 | — |
| CORRESP | Letter to the SEC | Jun 24, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2020 | — |
| D | Filing | Jun 11, 2020 | — |
| EFFECT | Filing | Jul 17, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CERT | 8a cert | Jul 15, 2019 | — |
| 8-A12B | Filing | Jul 12, 2019 | — |
| CORRESP | Letter to the SEC | Jun 26, 2019 | — |
| CORRESP | Letter to the SEC | Jun 21, 2019 | — |
| SEC STAFF LETTER | Filing | Jun 20, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 19, 2019 | — |
| DRS/A | Filing | Jun 6, 2019 | — |
| DRSLTR | Filing | Jun 5, 2019 | — |
| UPLOAD | Letter from the SEC | May 29, 2019 | — |
| SEC STAFF LETTER | Filing | May 13, 2019 | — |
| DRS | Filing | May 1, 2019 | — |
| D | Filing | Sep 5, 2018 | — |
| D/A | Filing | Jul 25, 2017 | — |
| D | Filing | May 10, 2017 | — |
| D | Filing | Jul 25, 2016 | — |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FULC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680581
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.